Effect of tolvaptan on renal handling of water and sodium, GFR and central hemodynamics in autosomal dominant polycystic kidney disease during inhibition of the nitric oxide system: a randomized, placebo-controlled, double blind, crossover study

Table 4 Effect of tolvaptan 60 mg at baseline, during and after systemic inhibition of NO synthesis on plasma concentrations of renin (PRC), angiotensin II (P-AngII) and aldosterone (P-Aldo) in a randomized, placebo-controlled, double-blind, crossover study of 18 ADPKD patients

Periods	Prior to L-NMMA infusion period	At the end of L-NMMA infusion period	1 h after L-NMMA infusion period	P (GLM-within)
PRC(pg/ml)
Placebo	8.8 ± 5.3	7.4 ± 4.0	7.7 ± 4.3	0.610
Tolvaptan 60 mg	10.1 ± 5.8	8.9 ± 6.1	8.4 ± 4.9	0.610
p (GLM between)	0.489
p (paired t-test, between)	0.481	0.312	0.523
P-AngII (pg/ml)
Placebo	7.8 ± 3.8	7.4 ± 3.8	7.1 ± 3.1	0.801
Tolvaptan 60 mg	9.1 ± 5.9	8.9 ± 4.7	8.6 ± 4.3	0.801
p (GLM between)	0.327
p (paired t-test, between)	0.377	0.151	0.261
P- Aldo (pmol/L)
Placebo	125 (68; 168)	127 (99; 224)	119 (87; 224)
Tolvaptan 60 mg	115 (87; 180)	147 (115; 205)	178 (108; 264)
p (Wilcoxon’s signed rank test, between)	0.420	0.433	0.170

Data are given as mean ± SD or median with 25th and 75th percentiles in parentheses. General linear model (GLM) with repeated measures was performed for comparison within and between groups. Post-hoc Bonferoni test was used for comparison between L-NMMA infusion period (at the end of L-NMMA infusion period) vs baseline (prior to L-NMMA infusion period) and at baseline vs post infusion period (1 h after L-NMMA infusion period) vs baseline period, none of the p- values were significant. Paired t-test was performed to test differences between treatment groups

ISSN: 1471-2369